Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

What do you think about BMC? Take part in

Case Reports

Section edited by Alfred Zippelius, MD

Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.

Previous Page Page 1 of 3 Next Page
  1. Content type: Case report

    Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with cancer, and studies using immunotherapy have show...

    Authors: Gustavo dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes and Renata de Almeida Coudry

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:84

    Published on:

  2. Content type: Case report

    Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of...

    Authors: Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi and Robert M. Conry

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:91

    Published on:

  3. Content type: Case report

    Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinu...

    Authors: Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal and David Jablons

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:75

    Published on:

  4. Content type: Case report

    Renal medullary carcinoma is one of the rarest malignancies arising from the kidney. Despite various aggressive therapeutic regimens, mortality remains significantly high (95%) with a median overall survival o...

    Authors: Quaovi Sodji, Kandy Klein, Kavuri Sravan and Jigarkumar Parikh

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:62

    Published on:

  5. Content type: Case report

    Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1...

    Authors: Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott and Toni K. Choueiri

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:66

    Published on:

  6. Content type: Case report

    The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopath...

    Authors: Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas and Stephane Dalle

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:57

    Published on:

  7. Content type: Case report

    Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patient...

    Authors: Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride and Andrew S. Kraft

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:58

    Published on:

  8. Content type: Case report

    The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur.

    Authors: Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner and Ben C. Creelan

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:54

    Published on:

  9. Content type: Case report

    Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen.

    Authors: Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon and Patrick A. Ott

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:61

    Published on:

  10. Content type: Case report

    The tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype, that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163. The pr...

    Authors: Michael C. Topf, Madalina Tuluc, Larry A. Harshyne and Adam Luginbuhl

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:60

    Published on:

  11. Content type: Case report

    Stimulation of the immune system by targeting the PD-1/PD-L1 pathway can result in activation of anti-tumor immunity. Besides its clinical benefit immune checkpoint therapy leads to significant immune-related ...

    Authors: Heinz Läubli, Jürgen Hench, Michal Stanczak, Ingmar Heijnen, Alexandros Papachristofilou, Stephan Frank, Alfred Zippelius and Frank Stenner-Liewen

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:46

    Published on:

  12. Content type: Case report

    Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically exclu...

    Authors: Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers and Hussein Tawbi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:45

    Published on:

  13. Content type: Case report

    We report the first case to our knowledge of a patient with relapsed/refractory classical hodgkin lymphoma and liver failure with encephalopathy along with human immunodeficiency virus/acquired immunodeficienc...

    Authors: Jose D. Sandoval-Sus, Francis Mogollon-Duffo, Ankita Patel, Nathan Visweshwar, Damian A. Laber, Richard Kim and Michael V. Jagal

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:49

    Published on:

  14. Content type: Case report

    Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence ...

    Authors: James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra and Colleen Veloski

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:40

    Published on:

  15. Content type: Case report

    Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic cas...

    Authors: Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot and Karim Fizazi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:31

    Published on:

  16. Content type: Case report

    Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of i...

    Authors: Samuel Rosner, Filiz Sen and Michael Postow

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:34

    Published on:

  17. Content type: Case report

    CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is t...

    Authors: Jeanelle King, Javier de la Cruz and Jose Lutzky

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:19

    Published on:

  18. Content type: Case report

    Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combi...

    Authors: James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek and Justin Kline

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:11

    Published on:

  19. Content type: Case report

    Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed...

    Authors: Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu and Tarik Hadid

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:13

    Published on:

  20. Content type: Case report

    Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-...

    Authors: Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka and Tarik Hadid

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:15

    Published on:

Previous Page Page 1 of 3 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement